XASX
DEM
Market cap22mUSD
Jul 10, Last price
0.09AUD
1D
-8.25%
1Q
3.49%
Jan 2017
-99.76%
IPO
-78.19%
Name
De.mem Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 2013 and headquartered in Melbourne, Australia, De.mem Limited specializes in the conceptualization, construction, ownership, and management of autonomous water and wastewater treatment infrastructure. Their services primarily cater to industrial, municipal, and residential clients throughout Australia, Singapore, and Germany. The company's technology portfolio is extensive, featuring advanced disinfection methods like chlorination and ultraviolet systems, alongside biological treatments such as aerobic and anaerobic processes, and diverse chemical dosing applications. A core offering involves various membrane-based water purification systems, including microfiltration, ultrafiltration, hollow fiber nanofiltration, reverse osmosis, membrane bioreactors, and forward osmosis. Complementing these are specialized processes like dissolved air flotation, media filtration, and ion exchange. Beyond core treatment solutions, De.mem provides sophisticated programmable logic controller and automation systems, as well as comprehensive sludge management services. Their expertise extends to delivering solutions for potable water, sewage treatment, industrial wastewater recycling, desalination, and process water requirements. Moreover, they offer full operational and maintenance support for treatment facilities, coupled with expert consulting, engineering, optimization, and technical advisory services. The company also engages in flexible business models such as Build-Own-Operate (BOO) and Build-Own-Operate-Transfer (BOOT). De.mem serves a broad spectrum of industries, including mining, infrastructure, electronics, chemicals, oil and gas, and food and beverage.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||